ALIPAY
On International Museum Day 2022, 4DAGE announced it landed virtual tours and exhibitions of 23 museums, including the historic Henan Museum and Zhejiang Provincial Museum in China and the Hetjens Museum in Germany, through a mini program on Alipay, the leading digital open platform. The collaboration between 4DAGE and Alipay provides China’s mobile-savvy audience an opportunity to better engage with and learn about the museums’ rich histories.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220518005528/en/
The mini program “Yunshang Mibao” (translated as “treasure hunting on the cloud”) launched on the Alipay platform provides users an immersive museum-visiting experience at their fingertips. They can appreciate the beauty of cultural relics in 3D and have a comprehensive tour of historical collections with Chinese narration.
These virtual exhibitions cover a wide range of subjects spanning 8,000 years of history, including Bronze Age civilization in the Yangtze river valley, dinosaurs in the Mesozoic Era and ceramics in the Rococo period.
“We are delighted to collaborate with museums and the Alipay platform to explore innovative ways to communicate the stories and histories of culture institutions to a wider range of museum and art lovers,” said Shen Ming, Director of International Cooperation from 4DAGE, the VR technology provider for the virtual tours.
“Alipay is committed to supporting the digital operations of brands and merchants to enhance their connection and engagement with consumers in China. Together with our partners, we are exploring digital solutions to meet museums’ evolving needs, including leveraging technology to bring their stories to a younger generation and open new commercialization opportunities,” said Xiaoqi Wang, Head of digital operations for culture and tourism sector at Alipay.
The partnership between 4DAGE and Alipay reflects Alipay’s continued commitment to help museums globally engage and deepen their relationship with China’s growing cultural arts and history community at time when international travel is affected by the COVID-19 pandemic.
To further celebrate this year’s International Museum Day, 28 Chinese museums are issuing newly launched creative digital collectibles on the Alipay mini program and the Topnod app, an Ant Group platform for collecting, exploring, and sharing digital collectibles.
A UNESCO report published in May 2020 showed the global museum industry has been severely impacted by COVID-19 with nearly 90% of museums worldwide closing their doors during the pandemic1 . However, less than 20% of museum collections were available online, according to a report by the Network of European Museum Organisations in July 20202 . Facing the pressing challenges brought by the pandemic, a growing number of museums start to leverage digital platforms and solutions, including online exhibitions, digital tours, and even livestreaming and blockchain technology powered digital collectibles, to better engage with museum lovers.
Including today’s announcement and a recent collaboration with nine Italian museums, over 2,000 museums have landed on the Alipay platform to enhance their digital operations and better connect with museum lovers. These museums are utilising at least one of the digital tools and services available on Alipay, such as mini programs, lifestyle accounts, and blockchain-powered digital collectibles.
About 4DAGE
Founded in 2014, 4DAGE has been dedicated to the studies and application of artificial intelligence in the field of three-dimensional digital reconstruction. As one of the first 3D digital reconstruction centers in China and one of the pioneering companies in 3D display technologies, 4DAGE provides products and solutions to major museums and expositions globally, including the Palace Museum, Nanchang Han Dynasty Haihunhou Historic Site Museum and World Expo. 4DAGE also serves industries ranging from industrial intelligence and smart city to real estate and new retail.
About Alipay
In the evolving digital era, Alipay has transformed from a payment tool of public trust to an open platform for businesses, institutions, service providers, and other partners. Business partners in various industries utilize Alipay to offer consumers a safe and convenient payment experience. Through digital operation, business partners can communicate and provide various commercial and daily life digital services for their clients via Alipay mini programs, lifestyle accounts, and IoT, along with other tools available. Currently, there have been over 80 million businesses serving more than 1 billion consumers via Alipay’s open platform services.
1
https://cimam.org/documents/102/Museums_around_the_world_in_the_face_of_COVID-19_-_UNESCO_Biblioteca_Digital.pdf
2
https://icom.museum/en/news/online-learning-teaching-digitised-collections/
View source version on businesswire.com: https://www.businesswire.com/news/home/20220518005528/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom